Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Financial Overview - Citius Pharmaceuticals raised $12.5 million in gross financings during the fiscal third quarter ended June 30, 2025, with an additional $9 million raised in July 2025 for LYMPHIR pre-launch initiatives [1][3] - The company reported a net loss of $9.2 million, or $0.80 per share, for the quarter, an improvement from a net loss of $10.6 million, or $1.57 per share, in the same quarter of the previous year [7][13] Business Development - Citius is transitioning from a development-stage enterprise to a fully integrated commercial organization, with final preparations for the U.S. launch of LYMPHIR™ planned for the fourth quarter of 2025 [2][3] - The company has completed major launch-enabling activities, including commercial-scale manufacturing and distribution agreements, indicating readiness to deliver LYMPHIR to patients with cutaneous T-cell lymphoma [3][6] Financial Results - Research and development expenses for the quarter were $1.6 million, down from $2.8 million in the same quarter of 2024 [7][15] - General and administrative expenses were $4.4 million, compared to $4.8 million in the prior year [7][15] - Cash and cash equivalents at June 30, 2025, were $6.1 million, an increase from $3.3 million at the end of the previous fiscal year [7][9] Capital Structure - The company completed a $6 million registered direct offering in June 2025, with potential additional proceeds of $9.8 million upon full warrant exercise [3][6] - Citius Oncology, a subsidiary, raised $9 million in gross proceeds from a public offering in July 2025 [1][3] Product Pipeline - Citius Pharma's late-stage pipeline includes LYMPHIR™, Mino-Lok®, and CITI-002 (Halo-Lido), with ongoing engagement with the FDA for next steps on these programs [6][3]